In a world where access to life-saving biologics is often limited, the demand for cost-effective biosimilar solutions is more critical than ever. With 25 years of legacy as a trusted CRO, we understand the complexities of bringing these vital products to market and have a proven track record in biosimilar development. Our expertise includes designing effective development plans and regulatory strategies for your biosimilars, ensuring successful program execution. 

Lambda has extensive experience in conducting clinical trials for biosimilars across multiple therapeutic areas, ensuring regulatory compliance and high-quality data generation. Our expertise includes pharmacokinetic (PK), pharmacodynamic (PD), immunogenicity, and efficacy studies for a range of biosimilars, including, Vedolizumab, Bevacizumab, Denosumab, Pertuzumab, Rituximab, Trastuzumab, Trastuzumab Emtansine, Aflibercept, Ranibizumab, and Teriparatide.